Gevotroline

From Wikipedia, the free encyclopedia

Other namesWY-47,384; WY-47384; WY47384
ATC code
  • None
Legal status
  • In general: uncontrolled
Gevotroline
Clinical data
Other namesWY-47,384; WY-47384; WY47384
Routes of
administration
Oral
ATC code
  • None
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • 8-fluoro-2-(3-pyridin-3-ylpropyl)-1,3,4,5-tetrahydropyrido[4,3-b]indole
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H20FN3
Molar mass309.388 g·mol−1
3D model (JSmol)
  • Fc2cc1c3c([nH]c1cc2)CCN(C3)CCCc4cccnc4

Gevotroline (WY-47,384) is an atypical antipsychotic with a tricyclic structure which was under development for the treatment of schizophrenia by Wyeth-Ayerst.[1][2][3] It acts as a balanced, modest affinity D2 and 5-HT2 receptor antagonist and also possesses high affinity for the sigma receptor.[2][4][5][6] It was well tolerated and showed efficacy in phase II clinical trials but was never marketed.[2][3]

References

Related Articles

Wikiwand AI